Navigation Links
NovaBay Pharmaceuticals to Present New Data on Lead Anti-Infective Compound at the 2009 ICAAC Annual Meeting
Date:8/21/2009

EMERYVILLE, Calif., Aug. 21 /PRNewswire-FirstCall/ -- NovaBay(R) Pharmaceuticals, Inc. (NYSE-Amex: NBY), a clinical stage company developing non-antibiotic anti-infective compounds for the treatment or prevention of a wide range of bacterial, viral, and fungal infections, will deliver two poster presentations at the 49th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) in San Francisco, CA. The two poster presentations will describe results from new studies of NVC-422, an Aganocide(R) compound.

Presentation details are as follows:

    Poster Title:     N,N-dichloro-2,2-dimethyltaurine (NVC-422) has
                      bactericidal activity against antiseptic and
                      antibiotic-resistant Staphylococcus aureus
    Date/Time:        Monday September 14, from 11:15 am to 1:15 pm
                      (Pacific Time)
    Session:          163. Miscellaneous
    Abstract Number:  E-1468
    Location:         Hall B

    Poster Title:     Antimicrobial activity of endogenous and stabilized
                      derivatives of N-chlorotaurines against representative
                      microorganisms in the presence of human plasma, serum
                      and albumin
    Date/Time:        Monday September 14, from 11:15 am to 1:15 pm
                      (Pacific Time)
    Session:          167-New Topical Antibacterial Agents Including Agents
                      against C. difficile
    Abstract Number:  F1-1526
    Location:         Hall B

"These findings support the compelling therapeutic profile of NVC-422 as a broad spectrum antimicrobial agent that carries little potential for resistance through common antiseptic resistance mechanisms," said Dr. Dmitri Debabov, poster co-author and assistant director of microbiology and acting head of biology of NovaBay Pharmaceuticals.

About Aganocide Compounds

The Aganocide compounds are novel, proprietary, synthetic N-chlorinated antimicrobial molecules specifically designed by NovaBay to mimic the body's natural defense against infection. The Aganocide compounds maintain the biological activities while improving the stability of naturally occurring N-chlorinated antimicrobial molecules. These highly differentiated compounds may deliver the same or better efficacy than currently used antibiotics without contributing to the growing rise of bacterial resistance. In preclinical trials, the Aganocide compounds have shown to be highly effective against bacteria, viruses and fungi. They have also been demonstrated to be effective against bacteria in biofilm, which render most antibiotics ineffective. These compounds have a potentially broad therapeutic index providing a high degree of potency, good tolerability and dosing versatility and flexibility.

About NovaBay Pharmaceuticals, Inc.

NovaBay Pharmaceuticals is a mid-stage biopharmaceutical company focused on developing its proprietary and patented Aganocide compounds, first-in-class, novel, synthetic anti-infective product candidates that are bioequivalent to the active antimicrobial molecules generated within white blood cells to treat and prevent a wide range of infections without causing resistance. NovaBay has internal development programs aimed at addressing hospital and respiratory infections. The company has a licensing and research collaboration agreement with Alcon, Inc. for use of its Aganocides in the eye, ear and sinus, and in contact lens solutions. NovaBay has entered into an agreement with Galderma S.A. to develop and commercialize Aganocides in acne, impetigo and other dermatological indications. NovaBay(R) and Aganocide(R) are trademarks of NovaBay Pharmaceuticals, Inc. For more information on NovaBay, visit www.novabaypharma.com.

Cautionary Information Regarding Forward-Looking Statements

The statements in this press release of NovaBay's expectations regarding the Aganocides possessing the characteristics of a broad spectrum antimicrobial agent that carries little potential for resistance and the development and commercialization of its Aganocide compounds through collaborations with corporate partners and other risks relating to NovaBay and its Aganocide compounds, including risks that could cause actual results to differ materially from those projected in the forward-looking statements in this press release, are detailed in NovaBay's Annual Report on Form 10-K, under the caption "Risk Factors" in Item 1A of Part I of that report, which was filed with the Securities and Exchange Commission on March 31, 2009.


'/>"/>
SOURCE NovaBay Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine technology :

1. Alcon Commences Phase 2 Clinical Trial of NovaBays NVC-422 for Viral Conjunctivitis
2. NovaBay(R) Pharmaceuticals Enters into Agreement to Broaden Intellectual Property Estate and Expand Clinical Opportunities for Its Aganocide(R) Compounds
3. NovaBay Pharmaceuticals Announces Lead Anti-infective Product Candidate, NVC-422, Shown to be Effective in Treating Topical Fungal Infection
4. Impax Pharmaceuticals Selects OmniComm Systems to Provide eClinical Solutions for International Phase III Study in Parkinsons Disease
5. Amira Pharmaceuticals Submits IND for Second DP2 Antagonist, AM461
6. Adamas Pharmaceuticals Signs CRADA With U.S. Navy to Conduct Preclinical Studies of Triple-Combination Antiviral Drug Therapy for Influenza A, Including the Novel H1N1 Pandemic Strain
7. Eiger BioPharmaceuticals Announces Initiation of CLEAN-1 HCV Phase 1b Trial
8. Access Pharmaceuticals Provides Update on ProLindac Clinical Development Program
9. Poniard Pharmaceuticals Announces Positive Cardiac Safety Data From Picoplatin Phase 1 Trial Supporting NDA Filing
10. Idenix Pharmaceuticals Successfully Completes Proof-of-Concept Study of IDX184 for the Treatment of Hepatitis C Virus (HCV)
11. Cardax Pharmaceuticals Nominates Clinical Candidate Heptax for Liver Disease; Heptax Ameliorates Inflammation and Oxidative Stress Related to Liver Disease and Metabolic Syndrome
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/25/2016)... , Deutschland und GERMANTOWN, Maryland ... Zusammenarbeit mit Therawis bedient ... bei Brustkrebs   QIAGEN N.V. (NASDAQ: ... gab heute bekannt, eine Lizenz- und Entwicklungsvereinbarung mit ... Assays für die Onkologie eingegangen zu sein. Ein ...
(Date:5/25/2016)... YORK , May 25, 2016  According to ... reached $381 billion in 2015.  Though these are ... plenty of opportunity for success for companies that ... in search of new growth prospects medical device ... on research and development (R&D) than do companies ...
(Date:5/25/2016)... NORTH CHESTERFIELD, Va. , May 25, 2016 ... commercially-available next-generation sequencing test for wounds and infections. ... fungi, ALL parasites, and select viruses. The test ... infected area. David G. ... advanced molecular testing to facilitate wound healing: "We ...
Breaking Medicine Technology:
(Date:5/27/2016)... ... , ... Aimed at nurses and employees in the health care world, this ... the nursing and health care industry. It also provides insight to the developing trends ... , As the nursing industry is coming out of one of the biggest recessions ...
(Date:5/26/2016)... ... May 26, 2016 , ... Despite last week’s media ... Janet Yellen and company to wait until March 2017 for an interest rate increase, ... Mack Robinson College of Business. , “The Federal Open Market Committee (FOMC) dot charts ...
(Date:5/26/2016)... ... May 26, 2016 , ... Cabot Corporation, Pfizer, and ... according to court documents and SEC filings. A jury has returned a ... American Optical Corporation, Case No. BC588866, Los Angeles County, California. The jury awarded ...
(Date:5/26/2016)... ... , ... Connor Sports, through its Connor Cares initiative, will continue ... Catchings Legacy Tour that will commemorate the Indiana Fever legend’s hall-of-fame career and ... forms and levels of the game, Connor Sports has committed to a significantly increased ...
(Date:5/26/2016)... ... May 26, 2016 , ... Cardiac arrhythmia is ... impact on long-term patient survival, reports a team of UPMC researchers in the ... in the Journal of Thoracic and Cardiovascular Surgery, provide critical information that will ...
Breaking Medicine News(10 mins):